BARCELONA, Spain and MARLBOROUGH, Mass., March 20, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced real-world data from the TRUE-HD study during a late-breaking clinical trial ...
New catheters and software enhancement expand capabilities of high-definition Rhythmia™ Mapping System MARLBOROUGH, Mass., Boston Scientific has received U.S. Food and Drug Administration (FDA) ...
* BOSTON SCIENTIFIC - WHEN COMPLETED, VALIDATION MAPPING IDENTIFIED NEED FOR ADDITIONAL ABLATIONS IN 73% OF PATIENTS Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results